Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.

Moxidectin

The articles shown below are all about the Moxidectin, through these related articles, you can get relevant information, notes in use, or latest trends about the Moxidectin. We hope these news will give you the help you need. And if these Moxidectin articles can't solve your needs, you can contact us for relevant information.
  • Drug Patent & Exclusivity Expiration Report - Week of June 09 2025

    Drug Patent & Exclusivity Expiration Report - Week of June 09 2025

    2025-06-09

    This week, there are 6 drugs in the patent and exclusivity list. They are: - NOVARTIS PHARMACEUTICALS CORP's TAFINLAR, containing active ingredient DABRAFENIB MESYLATE - NOVARTIS PHARMACEUTICALS CORP's MEKINIST, containing active ingredient TRAMETINIB DIMETHYL SULFOXIDE - COLLEGIUM PHARMACEUTICAL INC's XTAMPZA ER, containing active ingredient OXYCODONE - ELI LILLY AND CO's OLUMIANT, containing active ingredient BARICITINIB - MEDICINES DEVELOPMENT FOR GLOBAL HEALTH's MOXIDECTIN, containing active ingredient MOXIDECTIN - JAZZ PHARMACEUTICALS IRELAND LTD's ZEPZELCA, containing active ingredient LURBINECTEDIN Read More